Pharmacy Search
Vertice Login
Menu
close

Medmonitor

An up-to-date timeline of U.S. Food and Drug Administration (FDA) approvals that could potentially impact workers' compensation. These include new drug and indication approvals, new dosages or formulations of existing products, and generics introduced to the market. Click through the interactive timeline below, or select the comprehensive list view.
← Back to Medmonitor

Medication Type: Overdose

Revex (nalmefene) injection

Approval Date: Feb 2022

Note: First-Time Generic

A first-time generic of Revex, this drug is indicated for the complete or partial reversal of opioid drug effects, including respiratory depressions from natural or synthetic opioids, and for the management of opioid overdose

Zimhi™ (naloxone hydrochloride) injection

Approval Date: Oct 2021

Note: New Product

Indicated for the emergency treatment of known or suspected opioid overdose

KLOXXADO™ (NALOXONE HYDROCHLORIDE) NASAL SPRAY

Approval Date: Apr 2021

Note: New Product

For the emergency treatment of known or suspected opioid overdose. While other naloxone sprays were previously available in 2 mg and 4 mg doses, this drug has been approved at an 8 mg dose

Medication Name

Approval Date

Category

Description

Revex (nalmefene) injection

Feb 2022

A first-time generic of Revex, this drug is indicated for the complete or partial reversal of opioid drug effects, including respiratory depressions from natural or synthetic opioids, and for the management of opioid overdose

Note: First-Time Generic

Zimhi™ (naloxone hydrochloride) injection

Oct 2021

Indicated for the emergency treatment of known or suspected opioid overdose

Note: New Product

KLOXXADO™ (NALOXONE HYDROCHLORIDE) NASAL SPRAY

Apr 2021

For the emergency treatment of known or suspected opioid overdose. While other naloxone sprays were previously available in 2 mg and 4 mg doses, this drug has been approved at an 8 mg dose

Note: New Product
lockenvelopephone-handsetmagnifiermenucross-circle